secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0000950170-25-044801
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones
--------------------------------------------------------------------------------

- Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
- Upfront cash payment $10M; $9M paid at closing, $1M held in escrow for 15 months.
- Potential milestone payments up to $50M contingent on development, regulatory, and commercial milestones.
- Lilly assumes certain liabilities and will be responsible for all future clinical development of FXR314.
- Director Vaidehi Joshi resigned March 21, 2025, effective immediately, with no disagreement with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025044801/0000950170-25-044801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025044801/onvo-20250321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer